Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 157 in Subjects With Mild Atopic Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Tezepelumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 28 Dec 2020 Data from 7 studies (NCT00757042, NCT00972179, NCT01405963, NCT01913028, NCT02512900, NCT02525094 & NCT02054130) was used to develop a population PK model to guide tezepelumab dose selection for phase III trials in patients with severe asthma, published in the Journal of Clinical Pharmacology.
- 20 May 2014 Commentary published in the New England Journal of Medicine.
- 20 May 2014 Results published in the New England Journal of Medicine.